Search Result

Results for "

striatal dopamine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Dopamine Receptor (24) Dopamine Transporter (2) 5-HT Receptor (3) Adrenergic Receptor (1) Apoptosis (1) Bcl-2 Family (1) Calcium Channel (1) Cholinesterase (ChE) (3) COX (2) Deubiquitinase (1) Drug Derivative (1) Endogenous Metabolite (3) GlyT (1) iGluR (1) Isotope-Labeled Compounds (2) mAChR (2) mGluR (1) Mitophagy (1) Monoamine Oxidase (4) Monoamine Transporter (6) nAChR (5) NO Synthase (2) PARP (3) Reference Standards (6)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Metabolic Disease (1) Neurological Disease (41)

By Targets:

Dopamine Receptor (24)

Dopamine Transporter (2)

5-HT Receptor (3)

Adrenergic Receptor (1)

Apoptosis (1)

Bcl-2 Family (1)

Calcium Channel (1)

Cholinesterase (ChE) (3)

COX (2)

Deubiquitinase (1)

Drug Derivative (1)

Endogenous Metabolite (3)

GlyT (1)

iGluR (1)

Isotope-Labeled Compounds (2)

mAChR (2)

mGluR (1)

Mitophagy (1)

Monoamine Oxidase (4)

Monoamine Transporter (6)

nAChR (5)

NO Synthase (2)

PARP (3)

Reference Standards (6)

By Research Areas:

Cancer (1)

Cardiovascular Disease (1)

Metabolic Disease (1)

Neurological Disease (41)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Dopamine Receptor Dopamine β-hydroxylase Dopamine Transporter

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160019

MTX115325	Deubiquitinase Mitophagy	Neurological Disease
MTX115325 (Example 1) is an orally active, brain-penetrating USP30 inhibitor (IC₅₀=12 nM) with neuroprotective activity. MTX115325 increases ubiquitination (EC₅₀=32 nM) of the mitochondrial outer membrane protein TOM20 (a USP30 substrate), increasing mitophagy. MTX115325 prevents dopaminergic neuron loss and preserves striatal dopamine .

HY-B0590

Tetrabenazine 1 Publications Verification Ro 1-9569	Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-10435A

SKF-82958 hydrobromide 4 Publications Verification (±)-SKF-82958 hydrobromide; Chloro-APB hydrobromide	Dopamine Receptor	Neurological Disease
SKF-82958 ((±)-SKF 82958) hydrobromide is a dopamine D1 receptor full agonist (K_0.5=4 nM), displays selective for D1 over D2 receptors (K_0.5=73 nM). SKF-82958 hydrobromide induces dopamine D1 receptor-dependent adenylate cyclase activity in rat striatal membranes (EC₅₀=491 nM) .

HY-B0590S

Tetrabenazine-d6 Ro 1-9569-d₆	Monoamine Transporter	Neurological Disease
Tetrabenazine-d₆ (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-B1382

Pempidine 1,2,2,6,6-Pentamethylpiperidine	nAChR	Cardiovascular Disease Neurological Disease
Pempidine (1,2,2,6,6-Pentamethylpiperidine) is an orally active ganglionic blocking agent used in hypertension-related conditions. Pempidine is a nicotinic receptor blocker. Pempidine can antagonize the nicotine-induced increase of the striatal dopamine (DA) in vitro .

HY-145512

N-(α-Linolenoyl) tyrosine NLT	Dopamine Receptor	Neurological Disease
N-(α-Linolenoyl) tyrosine (NLT) is a dopaminergic agonist capable of crossing the blood-brain barrier. N-(α-Linolenoyl) tyrosine increases the level, turnover rate and release amount of dopamine in the striatum. N-(α-Linolenoyl) tyrosine modulates rotational behavior in a rat model with unilateral striatal injury and alleviates excessive blinking symptoms in models induced by dopamine-depleting agents. N-(α-Linolenoyl) tyrosine can be used for research on Parkinson's disease and idiopathic blepharospasm .

HY-Z0283

Benzamide 1 Publications Verification Benzenecarboxamide; Phenylamide	Endogenous Metabolite PARP	Others
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-107969

Haloperidol decanoate	Dopamine Receptor COX NO Synthase	Neurological Disease Cancer
Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D₂ receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia). Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model .

HY-159829

Direclidine NBI-1117568; HTL-0016878	mAChR	Neurological Disease
Direclidine (NBI-1117568, HTL-0016878) is a selective orthosteric agonist targeting the muscarinic acetylcholine M4 receptor, exhibiting very low affinity for M1, M2, M3, and M5 receptors. It binds to the orthosteric site of the M4 receptor in a non-covalent, competitive manner. Direclidine specifically activates the M4 receptor, inhibiting the release of acetylcholine from striatal cholinergic interneurons, thereby regulating the balance of the dopaminergic system and reducing psychiatric symptoms associated with excessive dopamine release. Direclidine can improve symptoms associated with neuropsychiatric disorders and is used in research on schizophrenia and other neuropsychiatric disorders .

HY-B1752

Quinpirole 4 Publications Verification LY 171555; (-)-LY 141865	Dopamine Receptor Calcium Channel Bcl-2 Family iGluR Apoptosis	Neurological Disease
Quinpirole (LY 171555; (-)-LY 141865) is a D2/D3 dopamine receptor agonist and a CaV1.3 calcium channel modulator. Quinpirole normalizes dendritic spine density in dopamine-depleted striatum, upregulates the protein expression of BCL2 and GluR2, downregulates the protein expression of BAX, and delays the onset of seizures. Quinpirole enhances learning and memory, inhibits neuronal apoptosis (apoptosis), and induces anxiety-like, stereotyped, and compulsive behaviors. Quinpirole disrupts prepulse inhibition in rhesus monkeys, enhances the activity of paraventricular thalamic neurons to promote recovery from Isoflurane anesthesia, and alters the composition of the gut microbiota in rats. Quinpirole can be used in research related to dyskinesia, pain, epilepsy, and neurological disorders including anxiety disorder, obsessive-compulsive disorder, and schizophrenia .

HY-120017

Befloxatone MD-370503	Monoamine Oxidase	Neurological Disease
Befloxatone (MD-370503) is an orally active, selective and reversible inhibitor of Monoamine Oxidase A (MAO-A) (IC₅₀=4 nM). Befloxatone increases the tissue level of monoamine, striatal dopamine and cortical norepinephrine. Befloxatone has antidepressant potential .

HY-B0590A

Tetrabenazine Racemate Ro 1-9569 Racemate	Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine (Ro 1-9569) Racemate is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine Racemate binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine Racemate weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine Racemate can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-B0884A

Minaprine dihydrochloride	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Minaprine dihydrochloride is a brain-penetrant monoamine oxidase inhibitor. Minaprine dihydrochloride also weakly inhibits acetylcholinesterase (AChE) activity. Minaprine dihydrochloride reduces intraneuronal dopamine metabolism, lowers striatal homovanillic acid and dihydroxyphenylacetic acid levels, and raises striatal 3-methoxytyramine and 5-hydroxytryptamine levels. Minaprine dihydrochloride exhibits convulsant, antidepressant properties .

HY-106584

Mosapramine Clospipramine	Drug Derivative Dopamine Receptor 5-HT Receptor	Neurological Disease
Mosapramine (Clospipramine) is an orally active antipsychotic agent and one of the metabolites of Clocapramine (HY-B2073) after oral absorption. Mosapramine exerts its effects by specifically binding to striatal dopamine D2 receptors and frontal lobe 5-HT2 receptors, with a D2/5-HT2 receptor occupancy ratio of 7.4. Mosapramine induces typical neuropharmacological responses in rat brain regions, including extrapyramidal symptoms, hyperprolactinemia, increased salivation, constipation, and upregulated Fos protein expression. Mosapramine also features a reduced incidence of weight loss. Mosapramine is applicable to research related to schizophrenia .

HY-100968

GBR 12783 dihydrochloride	Dopamine Receptor	Neurological Disease
GBR 12783 dihydrochloride is a specific, potent and selective *dopamine* uptake inhibitor that inhibits the [ ³H]dopamine uptake by rat and mice striatal synaptosomes with IC₅₀s of 1.8 nM and 1.2 nM, respectively. GBR 12783 dihydrochloride can improve memory performance and increase hippocampal acetylcholine release in rats .

HY-156331

VU6004909	mGluR	Neurological Disease
VU6004909 is a blood-brain barrier penetrated mGlu1 positive allosteric modulator (PAM), with the EC₅₀s of 25.7 nM and 31 nM for human mGlu1 and rat mGlu1, respectively. VU6004909 reduces dorsolateral striatal dopamine (DA) release in vivo and displays antipsychotic efficacy .

HY-152170

bPiDI 1 Publications Verification	nAChR	Neurological Disease
bPiDI is a novel selective α6β2 nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

HY-N2326

(±)-Anatoxin A fumarate	nAChR	Neurological Disease Metabolic Disease
(±)-Anatoxin A fumarate is a natural alkaloid isolated from freshwater cyanobacterium.(±)-Anatoxin A fumarate is a potent nicotinic receptor agonist and exhibits K_i values of 1.25 nM and 1.84 μM for binding to α4β2- and α7-type nicotinic receptors in rat brain membranes, respectively. (±)-Anatoxin A fumarate stimulates [ ³H]-dopamine release from rat striatal synaptosomes (EC₅₀=134 nM). (±)-Anatoxin A fumarate has toxic effect on fish .

HY-119468

Medifoxamine	Dopamine Transporter	Neurological Disease
Medifoxamine is an orally active monoamine reuptake inhibitor and antidepressant. Medifoxamine preferentially inhibits presynaptic dopamine reuptake. Medifoxamine acts as an intraocular pressure-lowering agent to reduce intraocular pressure, and also functions as a miotic agent to decrease pupil diameter. Medifoxamine exhibits characteristic properties of antidepressant compounds, including preventing hypothermia induced by Reserpine (HY-N0480) or Apomorphine (HY-12723), potentiating the toxic effects of Yohimbine (HY-N0127) in mice, and reducing immobility behavior in mice and rats in the "behavioral despair" model. Medifoxamine has no anticholinergic activity. Medifoxamine can be used in research related to depression .

HY-B0884

Minaprine	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Minaprine is a brain-penetrant monoamine oxidase inhibitor. Minaprine also weakly inhibits acetylcholinesterase (AChE) activity. Minaprine reduces intraneuronal dopamine metabolism, lowers striatal homovanillic acid and dihydroxyphenylacetic acid levels, and raises striatal 3-methoxytyramine and 5-hydroxytryptamine levels. Minaprine exhibits convulsant, antidepressant properties .

HY-107674

bPiDDB	nAChR	Neurological Disease
bPiDDB is a potent nAChR antagonist. bPiDDB potently (IC₅₀=2 nM) inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

HY-10435

SKF-82958 (±)-SKF-82958; Chloro-APB	Dopamine Receptor	Neurological Disease
SKF-82958 ((±)-SKF 82958) is a dopamine D1 receptor full agonist (K_0.5=4 nM), displays selective for D1 over D2 receptors (K_0.5=73 nM). SKF-82958 induces dopamine D1 receptor-dependent adenylate cyclase activity in rat striatal membranes (EC₅₀=491 nM) .

HY-W711852

Benzamide-d5 Benzenecarboxamide-d₅; Phenylamide-d₅	Isotope-Labeled Compounds PARP Endogenous Metabolite	Others
Benzamide-d₅ (Benzenecarboxamide-d₅) is deuterium labeled Benzamide. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-116550

Piroheptine hydrochloride	Dopamine Transporter	Neurological Disease
Piroheptine hydrochloride is an anticholinergic agent to inhibit dopamine uptake. Piroheptine hydrochloride prevents loss of striatal dopamine induced by MPTP (HY-15608). Piroheptine hydrochloride can be used for research in Parkinson .

HY-W008610

GBR 12783	Dopamine Receptor	Neurological Disease
GBR 12783 is a specific, potent and selective *dopamine* uptake inhibitor that inhibits the [ ³H]dopamine uptake by rat and mice striatal synaptosomes with IC₅₀s of 1.8 nM and 1.2 nM, respectively. GBR 12783 can improve memory performance and increase hippocampal acetylcholine release in rats .

HY-118461

PD 120697	Dopamine Receptor	Neurological Disease
PD 120697 is an orally active dopamine (DA) agonist. PD 120697 inhibits striatal DA synthesis, DA neuronal firing, spontaneous locomotor activity, and reverses Reserpine (HY-N0480)-induced depression .

HY-129682

LY125180	5-HT Receptor Dopamine Receptor Adrenergic Receptor	Neurological Disease
LY125180 is a serotonin uptake inhibitor. LY125180 competitively inhibits the uptake of serotonin and norepinephrine by cortical synaptosomes and of dopamine by striatal synaptosomes, with K_i values of 0.06 μM, 2.2 μM and 2.5 μM respectively .

HY-118706

PD 118440	Dopamine Receptor	Neurological Disease
PD 118440 is an orally active dopamine (DA) agonist. PD 118440 has significant central nervous system effects, including inhibition of striatal DA synthesis, suppression of DA neuron firing, and reversal of Reserpine (HY-N0480)-induced depression in rats .

HY-Z0283R

Benzamide (Standard) Benzenecarboxamide (Standard); Phenylamide (Standard)	Reference Standards Endogenous Metabolite PARP	Others
Benzamide (Standard) is the analytical standard of Benzamide. This product is intended for research and analytical applications. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-116450

TISCH	Dopamine Receptor	Neurological Disease
TISCH is a potent and selective iodinated ligand with high affinity and selectivity for CNS D1 dopamine receptors. TISCH showed a K_d value of 0.205 nM in rat striatal tissue, indicating its effectiveness in biological activity. TISCH is able to easily cross the blood-brain barrier and show distribution in specific areas with D1 receptor density. TISCH is considered to be useful as a pharmacological tool for characterizing D1 dopamine receptors. When labeled with I-123, TISCH has the potential to be used as an in vivo imaging agent for CNS D1 dopamine receptors .

HY-171328

RG-15	Dopamine Receptor	Neurological Disease
RG-15 is the orally active antagonist for dopamine receptor that exhibits goof affinity to human D2 receptor and human D3 receptor with pK_i of 8.23 and 10.49. RG-15 inhibits dopamine-stimulated [ ³⁵S]GTPγS binding with IC₅₀ of 21.2 nM (rat striatal membranes), 36.7 nM (mouse A9 cells expressing human D2L receptors) and 7.2 nM (CHO cells expressing human D3 receptors). RG-15 increases the turnover and biosynthesis of dopamine in mouse striatum and olfactory bulb, exhibiting antipsychotic activity .

HY-10435AR

SKF-82958 hydrobromide (Standard) (±)-SKF-82958 hydrobromide (Standard); Chloro-APB hydrobromide (Standard)	Reference Standards Dopamine Receptor	Neurological Disease
SKF-82958 (hydrobromide) (Standard) is the analytical standard of SKF-82958 (hydrobromide). This product is intended for research and analytical applications. SKF-82958 ((±)-SKF 82958) hydrobromide is a dopamine D1 receptor full agonist (K0.5=4 nM), displays selective for D1 over D2 receptors (K0.5=73 nM). SKF-82958 hydrobromide induces dopamine D1 receptor-dependent adenylate cyclase activity in rat striatal membranes (EC50=491 nM) .

HY-105793

Mazaticol	mAChR	Neurological Disease
Mazaticol is an anticholinergic agent. Mazaticol blocks the muscarinic acetylcholine receptors and cholinergic nerve activity. Mazaticol is a potent 3H-QNB and 3H-PZ binding inhibitor, can bind to the M2 receptors with high affinity. Mazaticol exhibits inhibitory effects on dopamine uptake in the striatal nerve terminal. Mazaticol can be used for parkinsonian syndrome research .

HY-107969R

Haloperidol decanoate (Standard)	Dopamine Receptor Reference Standards COX NO Synthase	Neurological Disease
Haloperidol decanoate (Standard) is the analytical standard of Haloperidol decanoate. This product is intended for research and analytical applications. Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D₂ receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia). Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model .

HY-B0590E

Tetrabenazine mesylate Ro 1-9569 mesylate	Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine (Ro 1-9569) mesylate is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine mesylate binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine mesylate weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine mesylate can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-B0590R

Tetrabenazine (Standard) Ro 1-9569 (Standard)	Reference Standards Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine (Standard) is the analytical standard of Tetrabenazine (HY-B0590). This product is intended for research and analytical applications. Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-B0590S3

Tetrabenazine-d7 TBZ-d7-d₇; Ro 1-9569-d₇	Isotope-Labeled Compounds Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine-d₇ (TBZ-d₇-d₇) is deuterium labeled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-B0884AR

Minaprine dihydrochloride (Standard)	Reference Standards Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Minaprine dihydrochloride (Standard) is the analytical standard of Minaprine dihydrochloride (HY-B0884A). This product is intended for research and analytical applications. Minaprine dihydrochloride is a brain-penetrant monoamine oxidase inhibitor. Minaprine dihydrochloride also weakly inhibits acetylcholinesterase (AChE) activity. Minaprine dihydrochloride reduces intraneuronal dopamine metabolism, lowers striatal homovanillic acid and dihydroxyphenylacetic acid levels, and raises striatal 3-methoxytyramine and 5-hydroxytryptamine levels. Minaprine dihydrochloride exhibits convulsant, antidepressant properties .

HY-180422

(-)-UH 232	Dopamine Receptor	Neurological Disease
(-)-UH 232 is a central dopamine (DA) receptor agonist. (-)-UH 232 weakly decreases 3, 4-dihydroxyphenylalanine (DOPA) formation in striatal and limbic brain regions in rats. (-)-UH 232 can be used for the research of neurological diseases including parkinson's disease and schizophrenia .

HY-107674R

bPiDDB (Standard)	Reference Standards nAChR	Neurological Disease
bPiDDB (Standard) is the analytical standard of bPiDDB (HY-107674). This product is intended for research and analytical applications. bPiDDB is a potent nAChR antagonist. bPiDDB potently (IC₅₀=2 nM) inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

HY-182381

FLA-797	Dopamine Receptor	Neurological Disease
FLA-797 is a brain-penetrant dopamine D2 receptor blocker and very low affinity for dopamine D1 receptors. FLA-797 selectively binds to and blocks postsynaptic dopamine D2 receptors. FLA-797 induces catalepsy in male rats. FLA-797 blocks dopamine agonist-induced hypothermia in male rats. FLA-797 contributes marginally to the dopamine D2 receptor-blocking activity of Remoxipride (HY-101313) in male rats. FLA-797 does not mimic the atypical antipsychotic profile of Remoxipride. FLA-797 can be used for research on mental disorders .

HY-124186

LR1143	Dopamine Receptor 5-HT Receptor	Neurological Disease
LR1143 is a dopamine transporter (DAT) and 5-HT uptake inhibitor, with IC₅₀ values of 3.4 nM and 112 nM in rats, respectively. LR1143 binds to DAT labeled with the dopamine reuptake inhibitor GBR 12935 (HY-12242A), with an IC₅₀ of 4.4 nM. LR1143 shows lower selectivity for DAT than for serotonin reuptake sites. LR1143 can be used in studies related to cocaine abuse .

HY-182484

Org 24461	GlyT	Neurological Disease
Org 24461 is a selective and brain-penetrant GlyT-1 inhibitor. Org 24461 blocks glycine uptake, reuptake, reverse operation, [ ³H]glycine efflux and release. Org 24461 enhances NMDA receptor function, modulates striatal monoamine/glutamate levels, and reverses PCP-induced behavioral and electrographic abnormalities. Org 24461 can be used for the research of retinal hypoxia/ischemia, and schizophrenia .

HY-W700204

N-(p-Aminophenethyl)spiperone	Dopamine Receptor	Neurological Disease
N-(p-Aminophenethyl) spiperone is a selective D₂-like dopamine receptor antagonist. N-(p-Aminophenethyl) spiperone binds to the ligand recognition sites of functional D₂ and D₃ dopamine receptors. N-(p-Aminophenethyl) spiperone serves as a research tool compound for labeling, localizing and identifying D₂ and D₃ dopamine receptors .

Cat. No.	Product Name	Target	Research Area

HY-145512

N-(α-Linolenoyl) tyrosine NLT	Dopamine Receptor	Neurological Disease
N-(α-Linolenoyl) tyrosine (NLT) is a dopaminergic agonist capable of crossing the blood-brain barrier. N-(α-Linolenoyl) tyrosine increases the level, turnover rate and release amount of dopamine in the striatum. N-(α-Linolenoyl) tyrosine modulates rotational behavior in a rat model with unilateral striatal injury and alleviates excessive blinking symptoms in models induced by dopamine-depleting agents. N-(α-Linolenoyl) tyrosine can be used for research on Parkinson's disease and idiopathic blepharospasm .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-Z0283

Benzamide 1 Publications Verification Benzenecarboxamide; Phenylamide	Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite PARP
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-Z0283R

Benzamide (Standard) Benzenecarboxamide (Standard); Phenylamide (Standard)	Structural Classification Alkaloids Human Gut Microbiota Metabolites Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite PARP
Benzamide (Standard) is the analytical standard of Benzamide. This product is intended for research and analytical applications. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

Cat. No.	Product Name	Chemical Structure

HY-B0590S

Tetrabenazine-d6

Tetrabenazine-d₆ (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-W711852

Benzamide-d5

Benzamide-d₅ (Benzenecarboxamide-d₅) is deuterium labeled Benzamide. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-B0590S3

Tetrabenazine-d7

Tetrabenazine-d₇ (TBZ-d₇-d₇) is deuterium labeled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks